Ocugen Nears Binary Moment as Phase 3 Enrollment Closes and Stock Sinks 55% From Peak

Ocugen shares trade at €1.05, down 55% from highs, as investors await key OCU400 data in early 2027; pipeline progresses but costs rise and market remains skeptical.

Investors in Ocugen are caught between a string of genuine clinical milestones and a stock that continues to drift near penny?territory. The shares recently changed hands around €1.05, down roughly nine percent since January and a staggering 55 percent below the March 2026 high of €2.35. The market is effectively pricing in no credit for the progress the biotech has reported — at least not yet.

The most concrete sign of that progress arrived with the completion of enrollment in liMeliGhT, Ocugen's largest trial to date. The Phase 3 study has recruited 140 patients across 17 sites in the United States and Canada. The experimental therapy, OCU400, is designed to treat retinitis pigmentosa by strengthening overall retinal health rather than targeting a single genetic mutation. Top?line data are expected in the first quarter of 2027, and if the numbers hold up, they would form the backbone of a Biologics License Application to the FDA. Approval, if it comes, would be unlikely before late 2027.

Meanwhile, the pipeline is widening. Ocugen has also finished the dosing phase of its Phase 2/3 trial for OCU410ST, a candidate directed at Stargardt disease — a rare inherited retinal disorder that affects an estimated 100,000 patients. The two programmes together represent a bet on platform?style gene therapies that could address multiple forms of vision loss with a single approach.

That ambition comes with rising costs. Research and development spending jumped 18 percent in the first quarter of 2026 to US$11.3 million, pushing the net loss per share wider year?on?year. Revenue inched up 3.5 percent to US$1.5 million, mostly from collaboration income, but remains negligible relative to the burn rate. The company's market capitalisation of roughly €350 million suggests investors are still demanding more concrete proof before they assign meaningful value to the pipeline.

Technically, the stock is flashing oversold signals. The relative strength index sits near 35, and the share price trades well below both the 50?day moving average of €1.30 and the 200?day average. The chart pattern points to exhaustion rather than accumulation. Yet sell?side analysts see a very different picture: their average price target stands at €9.84, implying upside of more than 800 percent from current levels. The gulf between Wall Street fantasy and market reality encapsulates the typical biotech dilemma — either the pivotal data hits and the targets become plausible, or the volatility claims another victim.

Ocugen now enters a waiting period that will test investor patience. The next hard data point is the OCU400 readout in early 2027, and until then, the stock is likely to oscillate near the €1 mark, buffeted by sentiment swings and the occasional conference presentation. CEO Shankar Musunuri has touted the company's gene?therapy advances at industry events, but shareholders have grown weary of slides without filings. The time for talk has passed; the market wants regulatory applications, and those are still months away.

For now, Ocugen remains a high?risk binary play. The upside scenario hinges on successful Phase 3 results and a subsequent FDA approval that would unlock a market of patients with few alternatives. The downside is that the stock drifts further into oversold territory, waiting for a catalyst that won't arrive until the first calendar quarter of 2027.